Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster

This article was originally published in Scrip

Executive Summary

Investors who backed a $50m Series C venture capital round for ARMO BioSciences are betting that the Redwood City, California-based company will be part of a second immuno-oncology wave with pegylated interleukins that are designed to boost the field's first wave of new therapies.

Advertisement

Related Content

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
Immuno-Oncology's Next Wave: Key Targets And Emerging Players

Topics

Advertisement
UsernamePublicRestriction

Register

SC064511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel